A recent study conducted by researchers and one that involved mice, has found a mechanism that may be used to explain the prosocial behavioral effects of LSD microdoses (lysergic acid diethylamide). The study, which was published in the “Proceedings of the National Academy of Sciences” journal, pioneers further research into whether LSD could be efficacious in treating ailments that negatively influence the social behavior of an individual.
In the recent past, microdosing has become a popular topic of discussion with regard to whether the method is an effective practice for the consumption of psychedelics. For those who may not be familiar with the term, microdosing refers to ingesting small amounts of a psychedelic substance in an attempt to improve an individual’s mood and/or cognitive function, among other things.
Anecdotal reports from individuals who microdose and that are cited in an article published in the “PLoS One” journal, claim that the practice has numerous positive effects in the long term on an individual’s well-being and health — only a few negative effects. However, there isn’t enough scientific evidence from empirical studies to support these claims.
Despite this, researchers have discovered that small LSD doses can increase an individual’s sense of trust, empathy, connection with others and happiness. This is in addition to separate studies discovering that LSD may also increase an individual’s positivity, altruism and sense of well-being in the long term.
To learn more about the possible biological mechanisms of the positive effects of LSD, researchers who conducted the aforementioned study carried out experiments using mice models In the study, a group of mice received a low dose of LSD every day for a week while a second group had only the vehicle which carried the psychedelic substance administered. This would allow the scientists to study the potential effects of the drug.
The researchers then carried out various tests using a method known as optogenetics, which involves utilizing light signals to deactivate signaling in the brains of mice, enabling the researchers to test any possible biological changes the psychedelic substance may affect.
This led to the discovery of an increase in the prosocial behavior of mice that had had tiny doses of LSD administered during the one-week period. In addition to this, the scientists also identified a mechanism that could account for this change.
The first author of the study, Dr. Danilo De Gregorio, explained that the increase in sociability occurred when LSD activated the AMPA receptors and the 5-HT2A serotonin receptors in the prefrontal cortex of the brain, which in turn led to the activation of the mTORC 1 cellular protein. De Gregorio also noted that these factors encouraged social interaction in mice, which is equal to social behavior and empathy in human beings.
With such proof that psychedelics could have a positive influence on behavior, it isn’t surprising that while companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) are focusing on using psychedelics to treat diseases such as sarcomas, other companies are looking in the mental health direction.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.